Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang
{"title":"乳腺癌预后的RAS通路生物标志物。","authors":"Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.</p>","PeriodicalId":91230,"journal":{"name":"Clinical laboratory international","volume":"40 ","pages":"18-23"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455995/pdf/nihms866728.pdf","citationCount":"0","resultStr":"{\"title\":\"RAS pathway biomarkers for breast cancer prognosis.\",\"authors\":\"Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.</p>\",\"PeriodicalId\":91230,\"journal\":{\"name\":\"Clinical laboratory international\",\"volume\":\"40 \",\"pages\":\"18-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455995/pdf/nihms866728.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory international\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory international","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
RAS pathway biomarkers for breast cancer prognosis.
Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
